Monday, July 13 delivered one of the busiest analyst days of the summer, with fresh Buy upgrades landing across payments, footwear, biotech, test-and-measurement, and less-than-truckload freight. Q2 earnings season begins in earnest this week — major banks report Tuesday through Thursday. The tape still sits against Chair Kevin Warsh's June 17 FOMC hold at 3.50%–3.75% and a CME FedWatch reading pricing roughly an 80% probability of zero rate cuts through year-end 2026. Five names drew fresh Buy signals worth watching into Tuesday, July 14.
American Express (AXP) — JP Morgan flips bullish on the payments giant
American Express is the largest US closed-loop payments network combined with a premium card-issuing bank, capturing merchant fees, interchange, and lending economics from a coveted higher-income customer base. On July 13, JP Morgan analyst Richard Shane upgraded the stock from Neutral to Overweight and raised his target from $328 to $400. The call arrived alongside a same-day HSBC maintained Hold that also lifted its target to $329 from $312 — the estimate revision cycle is tilting positive across the Street.
Shares traded at $354.61 midday July 13, up 1.15%, with a market cap of $242 billion and a trailing P/E of 22.12. Trailing EPS was $16.03 and the dividend yield is roughly 1%. The 52-week range is $288.34 to $387.49. The consensus rating is Buy, with 5 of 13 analysts bullish (38.5%), an average target of $370.15, a median of $380, a high of $415 held by Wells Fargo's Donald Fandetti, and a low of $324.
Risks: Card-member spend is directly tied to affluent-consumer confidence and any recession scenario would compress volumes; premium-card competitive intensity from Chase Sapphire and Capital One Venture X is elevated; the Consumer Financial Protection Bureau's review of late-fee caps remains an overhang; and BTIG's Vincent Caintic maintains a Sell rating at $307.
Deckers Outdoor (DECK) — Jefferies moves off the sidelines on Hoka and Ugg
Deckers is the parent of Hoka running shoes and Ugg lifestyle footwear, two of the fastest-growing consumer brands of the past five years with margin profiles that lead the athletic footwear peer group. On July 13, Jefferies analyst Blake Anderson upgraded the stock from Hold to Buy and raised his target from $110 to $130. Anderson himself held a Hold at $105 on January 27, so the move signals a genuine change of view.
Shares traded at $108.14 midday July 13, up 2.03%, with a market cap of $15.0 billion and a trailing P/E of 15.36. Trailing EPS was $7.04 and the company does not pay a dividend. The 52-week range is $78.91 to $126.50. The consensus rating is Buy, with 8 of 15 analysts bullish (53.3%), an average target of $121.73, a median of $125, a high of $161 from UBS analyst Jay Sole, and a low of $90.
Risks: Hoka's growth rate has decelerated from its peak and any further deceleration would test the multiple; Ugg is seasonally concentrated and a warm North American winter compresses fourth-quarter results; footwear peers including Nike are aggressively re-launching performance running to reclaim share; and Telsey Advisory Group's Dana Telsey holds a Market Perform at $120.
Biogen (BIIB) — Truist Securities lifts to Buy on the Alzheimer's franchise
Biogen is a large-cap biotech built around multiple sclerosis therapies (Tysabri, Tecfidera), spinal muscular atrophy franchise Spinraza, and the growing Leqembi Alzheimer's franchise co-developed with Eisai. On July 13, Truist Securities analyst Danielle Brill upgraded the stock from Hold to Buy and raised her target from $190 to $235 — a 24% hike and a full flip from the firm's prior Hold. RBC Capital's Brian Abrahams had lifted his Outperform target to $242 on July 7.
Shares jumped to $209.69 midday July 13, up 5.29%, with a market cap of $31.0 billion and a trailing P/E of 13.24. Trailing EPS was $15.84 and the company does not pay a dividend. The 52-week range is $121.05 to $219.72, with shares now near cycle highs. The consensus rating is Buy, with 12 of 18 analysts bullish (66.7%), an average target of $224.17, a median of $225, a high of $275, and a low of $150.
Risks: Leqembi launch trajectory remains uneven with reimbursement, infusion capacity, and PET-scan access all gating volume; MS franchise revenue is in secular decline as generic competition intensifies; pipeline binary readouts including for depression program zuranolone add volatility; and Piper Sandler's David Amsellem holds a Neutral at $177.
Keysight Technologies (KEYS) — Morgan Stanley joins the test-and-measurement bull camp
Keysight is a leading provider of electronic test-and-measurement instruments, software, and services used across communications, aerospace and defense, automotive, and semiconductor markets, with silicon test workflows for AI accelerators a growing tailwind. On July 13, Morgan Stanley analyst Meta Marshall upgraded the stock from Equal-Weight to Overweight and raised her target from $350 to $400. JP Morgan's Samik Chatterjee already holds Overweight at $390.
Shares traded at $321.31 midday July 13, down 0.23%, with a market cap of $54.9 billion and a trailing P/E of 37.06. Trailing EPS was $8.67 and the company does not pay a dividend. The 52-week range is $152.85 to $374.96. The consensus rating is Strong Buy, with 9 of 11 analysts bullish (81.8%), an average target of $379.36, a median of $390, a high of $425, and a low of $220.
Risks: Test-and-measurement demand is capex-linked and any wireless equipment slowdown weighs on core segments; semiconductor customer inventories can turn quickly if AI capex expectations moderate; competition from Rohde & Schwarz and National Instruments (now Emerson) is stiff in select workflows; and the trailing P/E of 37 leaves limited cushion if estimates disappoint.
Saia (SAIA) — Bank of America lifts to Buy on the LTL trucking story
Saia is a leading US less-than-truckload carrier, with a densifying terminal network built out via aggressive greenfield expansion over the past three years. On July 13, Bank of America analyst Ken Hoexter upgraded the stock from Neutral to Buy and raised his target from $499 to $502. The call follows a July 9 Citigroup upgrade from Ariel Rosa to Buy at $488 — a two-report positive cluster inside five sessions.
Shares traded at $430.86 midday July 13, up 2.39%, with a market cap of $11.5 billion and a trailing P/E of 47.30. Trailing EPS was $9.11 and the company does not pay a dividend. The 52-week range is $249.32 to $494.71. The consensus rating is Buy, with 11 of 17 analysts bullish (64.7%), an average target of $471.18, a median of $490, a high of $550 from Jefferies analyst Stephanie Moore, and a low of $295.
Risks: LTL tonnage remains sensitive to industrial and manufacturing output that has yet to fully re-accelerate; the aggressive terminal build-out inflates near-term operating ratios until utilization catches up; competitive pricing from XPO and Old Dominion is a constant; and Stifel's J. Bruce Chan holds a Hold at $381 well below the current share price.
Found this helpful? Share it with others.